Cargando…

Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study

BACKGROUND: Regional citrate anticoagulation (RCA) is the gold standard of anticoagulation for continuous renal replacement therapy but is rarely used for intermittent hemodialysis (IHD) in ICU. Few studies assessed the safety and efficacy of RCA during IHD in ICU; however, no data are available com...

Descripción completa

Detalles Bibliográficos
Autores principales: Leroy, Christophe, Pereira, Bruno, Soum, Edouard, Bachelier, Claire, Coupez, Elisabeth, Calvet, Laure, Bachoumas, Konstantinos, Dupuis, Claire, Souweine, Bertrand, Lautrette, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822996/
https://www.ncbi.nlm.nih.gov/pubmed/33481169
http://dx.doi.org/10.1186/s13613-021-00803-x
_version_ 1783639749344362496
author Leroy, Christophe
Pereira, Bruno
Soum, Edouard
Bachelier, Claire
Coupez, Elisabeth
Calvet, Laure
Bachoumas, Konstantinos
Dupuis, Claire
Souweine, Bertrand
Lautrette, Alexandre
author_facet Leroy, Christophe
Pereira, Bruno
Soum, Edouard
Bachelier, Claire
Coupez, Elisabeth
Calvet, Laure
Bachoumas, Konstantinos
Dupuis, Claire
Souweine, Bertrand
Lautrette, Alexandre
author_sort Leroy, Christophe
collection PubMed
description BACKGROUND: Regional citrate anticoagulation (RCA) is the gold standard of anticoagulation for continuous renal replacement therapy but is rarely used for intermittent hemodialysis (IHD) in ICU. Few studies assessed the safety and efficacy of RCA during IHD in ICU; however, no data are available comparing RCA to heparin anticoagulation, which are commonly used for IHD. The aim of this study was to assess the efficacy and safety of RCA compared to heparin anticoagulation during IHD. METHODS: This retrospective single-center cohort study included consecutive ICU patients treated with either heparin anticoagulation (unfractionated or low-molecular-weight heparin) or RCA for IHD from July to September in 2015 and 2017. RCA was performed with citrate infusion according to blood flow and calcium infusion by diffusive influx from dialysate. Using a propensity score analysis, as the primary endpoint we assessed whether RCA improved efficacy, quantified with Kt/V from the ionic dialysance, compared to heparin anticoagulation. The secondary endpoint was safety. Exploratory analyses were performed on the changes in efficacy and safety between the implementation period (2015) and at long term (2017). RESULTS: In total, 208 IHD sessions were performed in 56 patients and were compared (124 RCA and 84 heparin coagulation). There was no difference in Kt/V between RCA and heparin (0.95 ± 0.38 vs. 0.89 ± 0.32; p = 0.98). A higher number of circuit clotting (12.9% vs. 2.4%; p = 0.02) and premature interruption resulting from acute high transmembrane pressure (21% vs. 7%; p = 0.02) occurred in the RCA sessions compared to the heparin sessions. In the propensity score-matching analysis, RCA was associated with an increased risk of circuit clotting (absolute differences = 0.10, 95% CI [0.03–0.18]; p = 0.008). There was no difference in efficacy and safety between the two time periods (2015 and 2017). CONCLUSION: RCA with calcium infusion by diffusive influx from dialysate for IHD was easy to implement with stable long-term efficacy and safety but did not improve efficacy and could be associated with an increased risk of circuit clotting compared to heparin anticoagulation in non-selected ICU patients. Randomized trials to determine the best anticoagulation for IHD in ICU patients should be conducted in a variety of settings.
format Online
Article
Text
id pubmed-7822996
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-78229962021-01-29 Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study Leroy, Christophe Pereira, Bruno Soum, Edouard Bachelier, Claire Coupez, Elisabeth Calvet, Laure Bachoumas, Konstantinos Dupuis, Claire Souweine, Bertrand Lautrette, Alexandre Ann Intensive Care Research BACKGROUND: Regional citrate anticoagulation (RCA) is the gold standard of anticoagulation for continuous renal replacement therapy but is rarely used for intermittent hemodialysis (IHD) in ICU. Few studies assessed the safety and efficacy of RCA during IHD in ICU; however, no data are available comparing RCA to heparin anticoagulation, which are commonly used for IHD. The aim of this study was to assess the efficacy and safety of RCA compared to heparin anticoagulation during IHD. METHODS: This retrospective single-center cohort study included consecutive ICU patients treated with either heparin anticoagulation (unfractionated or low-molecular-weight heparin) or RCA for IHD from July to September in 2015 and 2017. RCA was performed with citrate infusion according to blood flow and calcium infusion by diffusive influx from dialysate. Using a propensity score analysis, as the primary endpoint we assessed whether RCA improved efficacy, quantified with Kt/V from the ionic dialysance, compared to heparin anticoagulation. The secondary endpoint was safety. Exploratory analyses were performed on the changes in efficacy and safety between the implementation period (2015) and at long term (2017). RESULTS: In total, 208 IHD sessions were performed in 56 patients and were compared (124 RCA and 84 heparin coagulation). There was no difference in Kt/V between RCA and heparin (0.95 ± 0.38 vs. 0.89 ± 0.32; p = 0.98). A higher number of circuit clotting (12.9% vs. 2.4%; p = 0.02) and premature interruption resulting from acute high transmembrane pressure (21% vs. 7%; p = 0.02) occurred in the RCA sessions compared to the heparin sessions. In the propensity score-matching analysis, RCA was associated with an increased risk of circuit clotting (absolute differences = 0.10, 95% CI [0.03–0.18]; p = 0.008). There was no difference in efficacy and safety between the two time periods (2015 and 2017). CONCLUSION: RCA with calcium infusion by diffusive influx from dialysate for IHD was easy to implement with stable long-term efficacy and safety but did not improve efficacy and could be associated with an increased risk of circuit clotting compared to heparin anticoagulation in non-selected ICU patients. Randomized trials to determine the best anticoagulation for IHD in ICU patients should be conducted in a variety of settings. Springer International Publishing 2021-01-22 /pmc/articles/PMC7822996/ /pubmed/33481169 http://dx.doi.org/10.1186/s13613-021-00803-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Leroy, Christophe
Pereira, Bruno
Soum, Edouard
Bachelier, Claire
Coupez, Elisabeth
Calvet, Laure
Bachoumas, Konstantinos
Dupuis, Claire
Souweine, Bertrand
Lautrette, Alexandre
Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study
title Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study
title_full Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study
title_fullStr Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study
title_full_unstemmed Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study
title_short Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study
title_sort comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in icu patients: a propensity score-matched cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822996/
https://www.ncbi.nlm.nih.gov/pubmed/33481169
http://dx.doi.org/10.1186/s13613-021-00803-x
work_keys_str_mv AT leroychristophe comparisonbetweenregionalcitrateanticoagulationandheparinforintermittenthemodialysisinicupatientsapropensityscorematchedcohortstudy
AT pereirabruno comparisonbetweenregionalcitrateanticoagulationandheparinforintermittenthemodialysisinicupatientsapropensityscorematchedcohortstudy
AT soumedouard comparisonbetweenregionalcitrateanticoagulationandheparinforintermittenthemodialysisinicupatientsapropensityscorematchedcohortstudy
AT bachelierclaire comparisonbetweenregionalcitrateanticoagulationandheparinforintermittenthemodialysisinicupatientsapropensityscorematchedcohortstudy
AT coupezelisabeth comparisonbetweenregionalcitrateanticoagulationandheparinforintermittenthemodialysisinicupatientsapropensityscorematchedcohortstudy
AT calvetlaure comparisonbetweenregionalcitrateanticoagulationandheparinforintermittenthemodialysisinicupatientsapropensityscorematchedcohortstudy
AT bachoumaskonstantinos comparisonbetweenregionalcitrateanticoagulationandheparinforintermittenthemodialysisinicupatientsapropensityscorematchedcohortstudy
AT dupuisclaire comparisonbetweenregionalcitrateanticoagulationandheparinforintermittenthemodialysisinicupatientsapropensityscorematchedcohortstudy
AT souweinebertrand comparisonbetweenregionalcitrateanticoagulationandheparinforintermittenthemodialysisinicupatientsapropensityscorematchedcohortstudy
AT lautrettealexandre comparisonbetweenregionalcitrateanticoagulationandheparinforintermittenthemodialysisinicupatientsapropensityscorematchedcohortstudy